Ancient Ig-Like Domain Controls Disease-Linked SWI/SNF Complexes
a (presumably primordial) Ig-like domain regulates the disease relevant SWI/SNF chromatin remodeling complexes that's pretty cool https://t.co/Iit0Swrx0I
Anti‑TGFβ1 Antibody Shows Durable Efficacy, Low Toxicity
Scholar Rock's anti-TGFb1 antibody clinical study with early data in oncology indications... minimal AEs and signs of durable efficacy in checkpoint-refractory patients. $SRRK https://t.co/8xsN4wtbMV
Grid Collapse Sparks Propane, Then Water Wars Amid Unprecedented Heat
What happens when the grid fails? Prediction: propane wars will precede water wars... you'll want to keep those emergency generators for AC running until you die of thirst.
FT Highlights CRUK's Aleta CAR‑T Trial in Lymphoma
The Financial Times covered recent initiatives at Cancer Research UK (CRUK) including a nice piece on the ongoing Aleta Biotherapeutics clinical trial in CD19-CAR-T treated B cell lymphoma patients. https://t.co/9sDZEItapu
Gene Therapy Leaps: Base Editing, CAR‑astrocytes, iPSC Approval
stunning week in cell and gene therapy: in vivo base editing of PCSK9 delivered via LNP, w clinical data (Nat Med), preclinical POC of CAR-astrocytes engineered w AAV (Science) and of self-amplifying RNA delivered IM (also Science), Japan approves gene...
Dual BCMA‑CD19 Targeting Shows Promise in ASyS
interesting and different efficacy outcomes in ASyS and SSc autoimmune patients treated with blinatumomab (CD3/CD19) and teclistamab (CD3/BCMA), respectively, + Rituximab maintenance. Potential for targeting both BCMA and CD19, especially in ASys. https://t.co/Dyq7h9EeGo
